Julian Harrison
Stock Analyst at BTIG
(4.63)
# 227
Out of 5,182 analysts
121
Total ratings
56.64%
Success rate
29.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reiterates: Buy | $38 | $15.34 | +147.72% | 4 | May 4, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $78 → $151 | $66.46 | +127.20% | 7 | Apr 27, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $151 → $178 | $86.89 | +104.86% | 5 | Apr 20, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $70 → $98 | $69.13 | +41.76% | 8 | Apr 13, 2026 | |
| AVTX Avalo Therapeutics | Reiterates: Buy | $40 | $13.78 | +190.28% | 4 | Apr 13, 2026 | |
| CLYM Climb Bio | Reiterates: Buy | $8 | $9.69 | -17.44% | 4 | Apr 8, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $4 | $1.50 | +166.67% | 5 | Apr 7, 2026 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $2.48 | +303.23% | 4 | Apr 1, 2026 | |
| TVRD Tvardi Therapeutics | Reiterates: Buy | $15 | $3.54 | +323.73% | 2 | Apr 1, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Buy | $30 | $17.56 | +70.84% | 6 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $46 | $26.93 | +70.81% | 6 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $137 | $83.55 | +63.97% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $16.89 | +24.33% | 6 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $39 | $24.52 | +59.05% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $50 | $38.48 | +29.94% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $22.99 | +52.24% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $117.13 | +28.06% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $7.30 | +132.88% | 3 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1 | $0.29 | +248.31% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.30 | +51.52% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $6.93 | +534.92% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $14.06 | +333.85% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $99.52 | -17.60% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.71 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $69.78 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.26 | +3,328.57% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $4.53 | +76.60% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.66 | +1,119.51% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.67 | +22,288.06% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $581.22 | - | 2 | Feb 11, 2022 |
Cullinan Therapeutics
May 4, 2026
Reiterates: Buy
Price Target: $38
Current: $15.34
Upside: +147.72%
Oruka Therapeutics
Apr 27, 2026
Maintains: Buy
Price Target: $78 → $151
Current: $66.46
Upside: +127.20%
Nektar Therapeutics
Apr 20, 2026
Maintains: Buy
Price Target: $151 → $178
Current: $86.89
Upside: +104.86%
Spyre Therapeutics
Apr 13, 2026
Maintains: Buy
Price Target: $70 → $98
Current: $69.13
Upside: +41.76%
Avalo Therapeutics
Apr 13, 2026
Reiterates: Buy
Price Target: $40
Current: $13.78
Upside: +190.28%
Climb Bio
Apr 8, 2026
Reiterates: Buy
Price Target: $8
Current: $9.69
Upside: -17.44%
Akebia Therapeutics
Apr 7, 2026
Reiterates: Buy
Price Target: $4
Current: $1.50
Upside: +166.67%
Connect Biopharma Holdings
Apr 1, 2026
Reiterates: Buy
Price Target: $10
Current: $2.48
Upside: +303.23%
Tvardi Therapeutics
Apr 1, 2026
Reiterates: Buy
Price Target: $15
Current: $3.54
Upside: +323.73%
MoonLake Immunotherapeutics
Mar 30, 2026
Reiterates: Buy
Price Target: $30
Current: $17.56
Upside: +70.84%
Mar 25, 2026
Reiterates: Buy
Price Target: $46
Current: $26.93
Upside: +70.81%
Mar 23, 2026
Reiterates: Buy
Price Target: $137
Current: $83.55
Upside: +63.97%
Mar 20, 2026
Reiterates: Buy
Price Target: $21
Current: $16.89
Upside: +24.33%
Mar 16, 2026
Maintains: Buy
Price Target: $28 → $39
Current: $24.52
Upside: +59.05%
Mar 5, 2026
Maintains: Buy
Price Target: $49 → $50
Current: $38.48
Upside: +29.94%
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $22.99
Upside: +52.24%
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $117.13
Upside: +28.06%
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $7.30
Upside: +132.88%
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.29
Upside: +248.31%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $3.30
Upside: +51.52%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.93
Upside: +534.92%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $14.06
Upside: +333.85%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $99.52
Upside: -17.60%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.71
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $69.78
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.26
Upside: +3,328.57%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $4.53
Upside: +76.60%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.66
Upside: +1,119.51%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.67
Upside: +22,288.06%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $581.22
Upside: -